Securities fraud litigation history and active cases
In Litigation
0
Settlement
1
Closed
0
Total Settlement
$9.5M
2:23cv23011 • December 11, 2023
Class Period Start
August 9, 2022
Class Period End
December 30, 2024
PSLRA Deadline
February 9, 2024
Case Allegations
10b5
Statutes of Repose
Aug 9, 2025
Country
United States
Court
Federal Court
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
October 16, 2026
Settlement Fund
$9,500,000
Settlement Status
Final Approval
Settlement Class
All persons or entities that purchased the publicly traded common stock of Eagle Pharmaceuticals, Inc. between August 9, 2022 and October 1, 2024, both dates inclusive.
Claim Administrator
Epiq
P.O. Box 4790
Portland, OR 97208-4790
+1 877-313-8718
[email protected]
Settlement Website
https://www.eaglepharmasecuritiessettlement.com/Hearing Date
August 19, 2026
Opt-out Deadline
July 29, 2026
Settlement Note
Download hereProof Of Claim
Download here
Aug 19, 2026
Final Approval of Settlement
Jul 15, 2026
Motion for Final Approval of Settlement
Jun 18, 2026
Notice of Pendency
Jun 18, 2026
Proof of Claim Form
May 20, 2026
Preliminary Approval of Settlement
Mar 26, 2026
Motion for Preliminary Approval of Settlement
Aug 25, 2025
Motion to Dismiss
Jul 11, 2025
First Amended Complaint
Aug 19, 2024
Appointment of Lead Plaintiff
Dec 11, 2023
First Filed Complaint
TOP
